<DOC>
	<DOCNO>NCT01258049</DOCNO>
	<brief_summary>The purpose study demonstrate ArTiMist ( sublingual artemether spray ) well intravenous quinine reduce parasite count &gt; = 90 % within 24 hour start treatment child severe malaria , uncomplicated malaria gastrointestinal complication</brief_summary>
	<brief_title>Superiority ArTiMist Versus Quinine Children With Severe Malaria</brief_title>
	<detailed_description>Malaria cause significant morbidity mortality child develop country , despite availability highly effective antimalarial therapy . One key contribute factor delay initiation treatment . ArTiMist sublingual formulation establish antimalarial treatment , artemether . In previous study good bioavailability demonstrate . In exploratory study ( ART003 ) ArTiMist demonstrate non statistically significant improvement 26 % ( compare intravenous quinine ) number patient experience parasite reduction &gt; = 90 % within 24 hour initiation treatment . This Phase 3 study conduct establish whether treatment ArTiMist child severe falciparum malaria uncomplicated falciparum malaria gastrointestinal complication least 20 % superior provide parasitological success ( defined &gt; = 90 % reduction parasite count 24 hour start treatment ) compare intravenous quinine .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Quinine</mesh_term>
	<criteria>1 . The patient 's legally acceptable representative provide informed consent patient assent ( relevant ) participation trial 2 . The patient child weigh 5.00 kg 15.00 kg inclusive 3 . The patient falciparum malaria evidence thick thin blood smear ≥ 500 P Falciparum per mcl ( patient mixed infection may include provide ≥ 500 P Falciparum per mcl ) 4 . The patient either : severe complicate falciparum malaria determine investigator base WHO criteria severity , and/or uncomplicated falciparum malaria unable tolerate oral medication result gastrointestinal complication vomit diarrhoea . 1 . The patient 's legally acceptable representative provide inform consent participation , child capable , assent participation trial . 2 . Ability tolerate oral therapy 3 . Patient receive antimalarial therapy within 7 day prior first study drug administration . 4 . Patient evidence significant coinfections ( include mixed Plasmodium infection ) . 5 . Patient contraindication , allergy otherwise intolerant either artemether quinine .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Plasmodium infection</keyword>
	<keyword>Remittent fever</keyword>
	<keyword>Artemether</keyword>
	<keyword>Artemesinins</keyword>
	<keyword>Quinine</keyword>
	<keyword>Malaria</keyword>
	<keyword>Protozoan infection</keyword>
	<keyword>sublingual drug delivery</keyword>
	<keyword>Parasitic disease</keyword>
	<keyword>Antiprotozoan agent</keyword>
</DOC>